Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 5/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.44 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12295637 | 0.86 | RXRA (0.43) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL19471078 | 0.86 | RXRA (0.43) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL508640 | 0.86 | RXRA (0.43) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL28946384 | 0.84 | RXRA (0.41) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL8087729 | 0.81 | RXRA (0.40) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL19211427 | 0.79 | NOTUM (0.67) | RXRAGRIN1GRIN2BNOTUMP2RX7 | |
| SCHEMBL2215780 | 0.79 | NOTUM (0.62) | NOTUMPOLBMAPT | |
| SCHEMBL19120213 | 0.78 | RXRA (0.40) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL22897584 | 0.78 | RXRA (0.40) | RXRAGRIN1GRIN2BL3MBTL1POLB | |
| SCHEMBL31465996 | 0.78 | HTT (0.47) | RXRAGRIN1GRIN2BL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-2547678-B1 | ANTI-INFECTIVE COMPOUNDS | PASTEUR INSTITUT KOREA (KR) | 2016-03-16 | — | — | EP | disclosed |
| US-9198913-B2 | Nitroimidazooxazines and their uses in anti-tubercular therapy | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2015-12-01 | — | — | US | disclosed |
| WO-2015179697-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | disclosed |
| US-9029389-B2 | Anti-inflammation compounds | INSTITUT PASTEUR KOREA (KR) | 2015-05-12 | — | — | US | disclosed |
| EP-2459571-B1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEV (US) | 2015-03-11 | — | — | EP | disclosed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | disclosed |
| US-8865734-B2 | Anti-infective compounds | INSTITUT PASTEUR KOREA (KR) | 2014-10-21 | — | — | US | disclosed |
| US-20140155387-A1 | Anti-Inflammation Compounds | QURIENT, CO. LTD. (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20140155387-A1 | Anti-Inflammation Compounds | QURIENT, CO. LTD. (KR) | 2014-06-05 | — | — | US | disclosed |
| US-20130065884-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2013-03-14 | — | — | US | disclosed |
| US-20130065884-A1 | Anti-Infective Compounds | INSTITUT PASTEUR KOREA (KR) | 2013-03-14 | — | — | US | disclosed |
| EP-2459571-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | Global Alliance For Tb Drug Development (US) | 2012-06-06 | — | — | EP | disclosed |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2012-02-02 | — | — | US | disclosed |
| WO-2011113606-A1 | ANTI-INFECTIVE COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011014774-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT (US) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ELANE, MMP8, NISCH | RXRA 1765/4885GRIN1 4143/4885GRIN2B 4237/4885 |
| US-20120028973-A1 | NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY | NOX5, MT-ND5, NQO1 | RXRA 2473/4885GRIN1 3584/4885GRIN2B 3799/4885 |
| US-20130065884-A1 | Anti-Infective Compounds | RABGGTB, ELANE, SERPINB1 | RXRA 2055/4885GRIN1 4349/4885GRIN2B 4590/4885 |
| US-20140155387-A1 | Anti-Inflammation Compounds | NR0B1, NR0B2, NR5A2 | RXRA 484/4885GRIN1 266/4885GRIN2B 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.